8
0
Teleflex Inc (NYSE:TFX) benefited in the first quarter from the surge in the interventional segment and other tailwinds.
UroLift sales in the physician’s office could bottom out at $49 million in 2024 and the franchise will be “less of a revenue headwind” from 2025, according to Piper Sandler.
The Teleflex Analyst: Matt O’Brien upgraded the rating for Teleflex from Neutral to Overweight, while raising the price target from $205 to $245.
The Teleflex Thesis: UroLift sales, which has prevented the stock from performing in recent quarters, should trough in the second or …
Full story available on Benzinga.com
Visited 8 times, 1 visit(s) today